These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 21220476)

  • 1. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
    Bagnato A; Rosanò L
    Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
    Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
    Rosanò L; Spinella F; Di Castro V; Nicotra MR; Dedhar S; de Herreros AG; Natali PG; Bagnato A
    Cancer Res; 2005 Dec; 65(24):11649-57. PubMed ID: 16357176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
    Cianfrocca R; Tocci P; Spinella F; Di Castro V; Bagnato A; Rosanò L
    Life Sci; 2012 Oct; 91(13-14):550-6. PubMed ID: 22480520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
    Rosanò L; Spinella F; Di Castro V; Decandia S; Nicotra MR; Natali PG; Bagnato A
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1128-31. PubMed ID: 16741062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
    Kajiyama H; Shibata K; Terauchi M; Yamashita M; Ino K; Nawa A; Kikkawa F
    Int J Oncol; 2007 Aug; 31(2):277-83. PubMed ID: 17611683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
    Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.
    Sestito R; Cianfrocca R; Rosanò L; Tocci P; Semprucci E; Di Castro V; Caprara V; Ferrandina G; Sacconi A; Blandino G; Bagnato A
    Oncotarget; 2016 Jan; 7(4):4009-23. PubMed ID: 26675258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of the endothelin axis in ovarian tumor progression.
    Bagnato A; Spinella F; Rosanò L
    Endocr Relat Cancer; 2005 Dec; 12(4):761-72. PubMed ID: 16322321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
    Ghoul A; Serova M; Astorgues-Xerri L; Bieche I; Bousquet G; Varna M; Vidaud M; Phillips E; Weill S; Benhadji KA; Lokiec F; Cvitkovic E; Faivre S; Raymond E
    Cancer Res; 2009 May; 69(10):4260-9. PubMed ID: 19417139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
    Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
    Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
    Rosanò L; Di Castro V; Spinella F; Decandia S; Natali PG; Bagnato A
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1132-5. PubMed ID: 16741063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
    Chan DW; Liu VW; Tsao GS; Yao KM; Furukawa T; Chan KK; Ngan HY
    Carcinogenesis; 2008 Sep; 29(9):1742-50. PubMed ID: 18632752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
    Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
    FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
    Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
    Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.